Xenetic Biosciences (NASDAQ:XBIO) Given “Neutral” Rating at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Xenetic Biosciences (NASDAQ:XBIO) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright also issued estimates for Xenetic Biosciences’ Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.84) EPS and Q4 2025 earnings at ($0.88) EPS.

Xenetic Biosciences Stock Performance

Shares of XBIO stock opened at $3.37 on Thursday. The firm’s 50-day moving average is $3.98 and its 200-day moving average is $3.99. The stock has a market cap of $5.20 million, a price-to-earnings ratio of -1.27 and a beta of 2.17. Xenetic Biosciences has a 52-week low of $2.78 and a 52-week high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last issued its earnings results on Tuesday, March 18th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48). The firm had revenue of $0.65 million during the quarter, compared to the consensus estimate of $0.18 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. Sell-side analysts predict that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Xenetic Biosciences stock. LGT Group Foundation purchased a new stake in Xenetic Biosciences Inc (NASDAQ:XBIO) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned 0.71% of Xenetic Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.